MYELOSUPPRESSION in English translation

• myelosuppression
• myelosupression

Examples of using Myelosuppression in Danish and their translations into English

især i form af myelosuppression, og sådanne patienter bør overvåges nøje for udvikling af svær myelosuppression..
particularly from myelosuppression, and such patients should be closely monitored for development of profound myelosuppression..

Hæmatologi I den første måned efter behandling er myelosuppression yderst vigtig,
Haematology During the first month following treatment, myelosuppression is most notable

Infektioner og maligniteter som forårsager myelosuppression Neutropeni kan være forårsaget af opportunistiske infektioner i knoglemarven, såsom Mycobakterie avium- kompleks, eller maligniteter, såsom lymfomer.
Infections and malignancies causing myelosuppression Neutropenia may be due to bone marrow-infiltrating opportunistic infections such as Mycobacterium avium complex or malignancies such as lymphoma.

Myelosuppression synes at forekomme mindre
Myelosuppression appeared to be less frequent

Infektioner og maligne sygdomme, der forårsager myelosuppression Neutropeni kan forekomme i forbindelse med opportunistiske infektioner, der infiltrerer knoglemarven, såsom Mycobacterium avium- kompleks eller ved maligne sygdomme som lymfom.
Infections and malignancies causing myelosuppression Neutropenia may be due to bone marrow infiltrating opportunistic infections such as Mycobacterium avium complex or malignancies such as lymphoma.

Myelosuppression var forudsigelig(sædvanligvis inden for de første få serie med nadir mellem dag 21
Myelosuppression was predictable(usually within the first few cycles, with the nadir between Day 21

Mange patienter, der behandles med Caelyx, har baseline- myelosuppression som følge af faktorer såsom deres præeksisterende HIV- sygdom
Many patients treated with Caelyx have baseline myelosuppression due to such factors as their pre-existing HIV disease

Øget neurotoksicitet, arthralgi/ myalgi, men nedsat myelosuppression blev set hos patienter med fremskreden ovariekræft, der fik givet 3 timers infusion af paclitaxel/ cisplatin sammenlignet med patienter, der fil cyklofosfamid/ cisplatin.
Increased neurotoxicity, arthralgia/ myalgia but reduced myelosuppression were observed in advanced ovarian cancer patients administered 3 hour infusion paclitaxel/ cisplatin as compared to patients who received cyclophosphamide/ cisplatin.

I den centrale undersøgelse hos patienter med ovariecancer behandlet med en dosis på 50 mg/ m2, var myelosuppression generelt let til moderat,
In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/ m2, myelosuppression was generally mild to moderate,

Under behandlingen skal patienten monitoreres for myelosuppression, og pemetrexed må ikke gives til patienter, før det absolutte neutrofiltal(ANC) igen er ≥ 1. 500 celler/ mm3, og trombocyt- tallet igen er ≥ 100. 000 celler/ mm3.
Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count(ANC) returns to≥ 1500 cells/ mm3 and platelet count returns to≥ 100,000 cells/ mm3.

Kliniske undersøgelser af AIDS- KS patienter behandlet med 20 mg/ m2 Caelyx viser, at myelosuppression var den hyppigste bivirkning, der anses for at være forbundet med Caelyx- behandling, forekommende meget almindeligt hos omkring en halvdel af patienterne.
Clinical studies on AIDS-KS patients treated at 20 mg/ m2 with Caelyx show that myelosuppression was the most frequent undesirable effect considered related to Caelyx occurring very commonly in approximately one-half of the patients.

har haft alvorlig myelosuppression.
have severe myelosuppression.

Meget almindelige: pancytopeni/ myelosuppression*, purpura Almindelige: petecchier, blødninger.
Very common: pancytopenia/ myelosuppression*, purpura Common: petechiae, haemorrhages.

Myelosuppression og levertoksicitet blev identificeret som den primære toksicitet i forbindelse med trabectedin.
Myelosupression and hepatoxicity were identified as the primary toxicity for trabectedin.

Myelosuppression er normalt den dosisbegrænsende toksicitet.
Myelosuppression is usually the dose-limiting toxicity.

Myelosuppression er derfor almindelig.
Myelosuppression is thus common.

Infektioner Myelosuppression kan føre til neutropeni
Infections Myelosupression may lead to neutropenia

Restitution efter myelosuppression sker normalt hurtigt, når behandlingen seponeres.
Recovery from myelosuppression is usually rapid when therapy is discontinued.

Den hyppigst indberettede bivirkning er myelosuppression med neutropeni som den mest almindelige manifestation.
The most frequently reported adverse reaction is myelosuppression with neutropenia as the most common manifestation.

Vedvarende alvorlig myelosuppression kan medføre superinfektion eller blødning.
Persistent severe myelosuppression, may result in superinfection or haemorrhage.